PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
53.82%
Cash & equivalents yoy growth 0.5-0.75x TRAW's 80.52%. Martin Whitman would worry if slower accumulation signals weaker operations or bigger outflows.
No Data
No Data available this quarter, please select a different quarter.
53.82%
Cash + STI yoy 0.5-0.75x TRAW's 80.52%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
54.98%
0.5-0.75x TRAW's 74.49%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-8.67%
Below half TRAW's -25.00%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.00%
Below half of TRAW's -21.05%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
53.46%
0.5-0.75x TRAW's 73.03%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
21.21%
Above 1.5x TRAW's 13.71%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-57.02%
Exceeding 1.5x TRAW's -16.14%. Michael Burry suspects ballooning short-term obligations vs. competitor.
37.02%
Above 1.5x TRAW's 5.77%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.02%
Less than half of TRAW's -2.21%. David Dodd sees far fewer liability expansions relative to competitor.
37.77%
Less than half of TRAW's 2325.00%. David Dodd sees fewer share issuances vs. competitor.
-3.87%
≥ 1.5x TRAW's -1.40%. David Dodd sees higher yoy retained profits than competitor.
-5.55%
Less than half of TRAW's 266.67%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
59.08%
≥ 1.5x TRAW's 34.09%. David Dodd sees stronger capital base growth than competitor.
53.46%
0.5-0.75x TRAW's 73.03%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-53.82%
50-75% of TRAW's -80.52%. Bruce Berkowitz notes comparatively lower net debt expansion.